1 Ferrara Musella BACS

8/10/2019 1 Ferrara Musella BACS

1/18

BACSBrief Assessment

Cognition Schizophrenia

Dr. ssa Maria Ferrara

Dr. Vincenzo Musella

Dipartimento di Salute Mentale-DP

AUSL Modena

[email protected]


2/18

!

i pazienti affetti da psicosipresentano disturbi cognitivi

!sin dallesordio sono presenti

a l te raz ion i ne l l e funz ion iesecutive, nella memoria verbale

e nelle capacit attentive [1,2].

!i disturbi cognitivi sono migliori

predittori del funzionamentocompless ivo (comuni tar io ,

occupazionale) del soggetto,rispetto alle misurazioni della

sintomatologia [3].

I disturbi cognitivi nellapsicosi


3/18


4/18


5/18


6/18

I disturbi cognitivi negliesordi psicotici.

correlazione coi farmaci

Recenti RCT hanno mostrato che i pazientic h e a s s u m o n o S G A s h a n n o u n aperformance migliore nei test cognitivi

rispetto a chi assume FGAsCi pu essere dovuto a :-

minori EPS " pi veloci (dal PDVmotorio)

- minor uso di anticolinergici (che possonoinficiare la memoria)

-

migliore efficacia su sintomi negativi(umore, motivazione)

-

effetto farmacologico diretto dei SGAs suimeccanismi biologici che sottendono lamalattia stessa.


7/18

Strumenti disponibili! " # ! $ %

'( )*+

, - % . !

/0 )*+

1-%2.,$

3' )*+

4 - , $

'0 )*+

%!$% ,56+*7*89 :;+4'*(0;*+ '*.' %T =0.4%9.>,'0,) -%(A0&6:*:%(5

10.4,) )*,(&0&6"# "# KGD#EUO

80./%&.0& /,(+ .%('0&6 '*.' EV*/4'0=* T4&/'0%&0&6 "#

U,/* *:%'0%& +0./(0:0&,'0%& ',.A "%/0,) /%6&0'0%&

JD?#7 C?W#HI JE"J ? KR :0&SO">**+ %T 0&T%(:,'0%& >(%/*..0&6

"# "#

JD?#7 C?W#HI JE"J G KR :0&SO EV*/4'0=* T4&/'0%&0&6 "#

'X* **+ "#

J%-*( %T 7%&+%& EV*/4'0=* T4&/'0%&0&6 "#

J*.' +0 /%(.0 10.4% .>,'0,) :*:%(5

EUFEST: european first episode schizofrenia trial. CATIE: Clinical Antipsychotic Trials of Intervention

Effectiveness. MATRICS: measurement and treatment research to improve cognition in Schizofrenia. BACS:

Brief assessment of cognition in Schizofrenia

+ RBANS+ BAC


8/18

Strumenti disponibili

EUFEST: european first episode schizofreniatrial.

CATIE: Clinical Antipsychotic Trials ofIntervention Effectiveness

MATRICS: measurement and treatment

research to improve cognition in SchizofreniaBACS: Brief assessment of cognition in

Schizofrenia


9/18


10/18

BACSvalidata in italiano


11/18

Quali domini va adinvestigare? (1)

MEMORIA ED APPRENDIMENTO VERBALE

Ai pazienti saranno presentate 15 parole e gli sarrichiesto di ricordarne quante pi possibile.

Questa procedura ripetuta 5 volte


12/18



13/18



14/18



15/18



16/18

Come si acquista?

Dear XXX,

Thank you for your interest in purchasing the Italian BACS. Duke Universityholds the copyright for the BACS, and it is licensed through NeuroCog Trials,Inc. The licensing fee, which includes the manual, testing materials, and atraining DVD, is $1000 per site and allows limitless use under the license.Attached, please find an electronic copy of the licensing agreement. In orderto process your order, please enter your information in the bold andbracketed portions.

Please sign and send the completed agreement in PDFformat to:

[email protected]

Upon receiving the signed license agreement, we will generate an invoice.The invoice, which contains all payment information, will be sent to youelectronically, and upon receipt of payment, we will ship the materials to theaddress you provide. If you have any questions regarding the licensingagreement or the BACS, please dont hesitate to contact us via email [email protected] or the number below.

Best,Ashley


17/18

Bibliografia essenziale di riferimento

1.Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J:Neurocognitive function in clinically stable men with bipolar I disorder

or schizophrenia and normal control subjects. Biol Psychiatry 2004, 56(8):560569.

2. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Torrent C,

Goikolea JM, Corbella B, Snchez-Moreno J, Salamero M: Neuropsychological performance in

depressed and euthymic bipolar patients. Neuropsychobiology 2002, 46(Suppl 1):1621.

3. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson

DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA: Neuropsychology of first-

episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000,

157(4):549559.

4. Nuechterlein KH, Subotnik KL, Green MF, Ventura J, Asarnow RF, Gitlin MJ, Yee CM,

Gretchen-Doorly D, Mintz J. Neurocognitive predictors of work outcome in recent-onsetschizophrenia. Schizophr Bull. 2011 Sep;37 Suppl 2:S33-40.5. Allott K, Liu P, Proffitt TM, Killackey E. Cognition at illness onset as a predictor of laterfunctional outcome in early psychosis: systematic review and methodological critique.Schizophr Res. 2011 Feb;125(2-3):221-35. Epub 2010 Dec 15.6. Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK,

Addington J. The course of cognitive functioning over six months in individuals at clinicalhigh risk for psychosis. Psychiatry Res. 2012 Nov 15.


18/18

7. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, CoughenourL. The Brief Assessment of Cognition in Schizophrenia: reliability,sensitivity, and comparison with a standard neurocognitive battery.Schizophr Res. 2004 Jun 1;68(2-3):283-97.8. Anselmetti S, Poletti S, Ermoli E, Bechi M, Cappa S, Venneri A,

Smeraldi E, Cavallaro R. The Brief Assessment of Cognition inSchizophrenia. Normative data for the Italian population. NeurolSci. 2008 Apr;29(2):85-92

Bibliografia essenziale di riferimento

Documents

1 Ferrara Musella BACS